Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Dolutegravir/abacavir/lamivudine (Triumeq®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2365. 2015 Authors' conclusions Dolutegravir/abacavir/lamivudine (Triumeq®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Indexing Status Subject indexing assigned by NLM MeSH Adult; Anti-HIV Agents /administration & Cross-Over Studies; Dideoxynucleosides /administration & Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Heterocyclic Compounds, 3-Ring /administration & Lamivudine /administration & Male; Therapeutic Equivalency; Vaginal Creams, Foams, and Jellies; Young Adult; dosage /blood /pharmacokinetics; dosage /blood /pharmacokinetics; dosage /blood /pharmacokinetics; dosage /blood /pharmacokineticss Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32015000595 Date abstract record published 01/06/2015 |